Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Approved commercial products on market by Year
Approved commercial products on market (products)
Moderna Approved commercial products on market: 3.00 products in FY2025, up 50.0% from a year earlier.
Latest, FY2025
3.00
Period ended Dec 31, 2025
Change on a year earlier
+50.0%
2.00 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 1 (Description of Business).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Approved commercial products on market (products) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.00 | +50.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 2.00 | – | Form 10-K (filed 2025-02-21) ↗ |
Cite this data
StockData. (2026). Moderna Approved commercial products on market, annual FY2024–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/num-commercial-products
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.